Please wait
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________
FORM 6-K
__________________________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934
For the quarterly period ended March 31, 2026
Commission File Number 001-38332
__________________________________
QIAGEN N.V.
(Translation of registrant’s name into English)
__________________________________
Hulsterweg 82
5912 PL Venlo
The Netherlands
(Address of principal executive office)
__________________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ý Form 40-F o
QIAGEN N.V.
Form 6-K
Table of Contents
| | | | | | | | |
| Item | | Page |
Other Information | | |
Signatures | | |
Exhibit Index | | |
Other Information
On April 27, 2026, QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) issued a press release with details announcing preliminary Q1 2026 results and updating full-year 2026 adjusted EPS outlook. The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | | | | |
| | |
| QIAGEN N.V. | |
| |
| By: | /s/ Roland Sackers |
| | Roland Sackers |
| | Chief Financial Officer |
Date: April 30, 2026
Exhibit Index
| | | | | | | | |
Exhibit
No. | | Exhibit |
| | |
| | Press Release dated April 27, 2026 |